Author of

• 12648

  +

  P3.11 - Poster Session 3 - NSCLC Novel Therapies (ID 211)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12650

    +

    P3.11-002 - New toxicity profile as radiological response marker in the context of mTOR therapy in advanced/metastatic non small cell lung cancer (NSCLC) (ID 293)

    09:30 - 09:30  |  Author(s): J. Martinez
    • Abstract

    Background
    mTOR pathway plays a key role in most of solid tumors. Its blockage has shown clinical and survival benefit in the context of advanced/metastatic breast, kidney and neutroendocrine cancer. Multiple preclinical and early clinical trials are ongoing to demonstrate mTOR inhibition role as monotherapy as in chemo combo in NSCLC.

    Methods
    Retrospective analysis of advanced and/or metastatic NSCLC patients treated in our Institution with mTOR monotherapy or combined chemotherapy and correlation between radiological cavitation pattern mTOR therapy induced as early response marker.

    Results
    Four patients with advanced/metastastic NSCLC in progression after more or equal 2 lines of standard chemotherapy were treated in our center during 2012 in the context of early clinical trials. Three patients had squamous NSCLC and one patient adenocarcinoma. All ones were evaluated at 6-8 weeks by CT scan: cavitation as early response marker was seen in all of them but measurement by RECIST 1.1 criteria only showed stable disease.

    Conclusion
    Preliminary data suggest that cavitation may be a marker of stable disease by RECIST and the therefore, a therapeutic benefit. Overinfection and haemoptysis are currently complications in this context. Careful patient assessment should be undertaken while the drug is being administered.